Recursion Pharmaceuticals Inc (RXRX) - Total Assets
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) holds total assets worth $1.40 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Recursion Pharmaceuticals Inc (RXRX) net assets for net asset value and shareholders' equity analysis.
Recursion Pharmaceuticals Inc - Total Assets Trend (2019–2024)
This chart illustrates how Recursion Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Recursion Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Recursion Pharmaceuticals Inc's total assets of $1.40 Billion consist of 49.3% current assets and 50.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.0% |
| Accounts Receivable | $49.17 Million | 3.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $335.86 Million | 23.2% |
| Goodwill | $148.87 Million | 10.3% |
Asset Composition Trend (2019–2024)
This chart illustrates how Recursion Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Recursion Pharmaceuticals Inc (RXRX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Recursion Pharmaceuticals Inc's current assets represent 49.3% of total assets in 2024, a decrease from 75.3% in 2019.
- Cash Position: Cash and equivalents constituted 41.0% of total assets in 2024, down from 68.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 23.2% of total assets.
Recursion Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Recursion Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Recursion Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.60 | 4.35 | 11.53 |
| Quick Ratio | 4.60 | 4.35 | 11.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $559.00 Million | $365.28 Million | $243.34 Million |
Recursion Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Recursion Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.74 |
| Latest Market Cap to Assets Ratio | 1.20 |
| Asset Growth Rate (YoY) | 121.6% |
| Total Assets | $1.45 Billion |
| Market Capitalization | $1.74 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Recursion Pharmaceuticals Inc's assets above their book value (1.20x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Recursion Pharmaceuticals Inc's assets grew by 121.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Recursion Pharmaceuticals Inc (2019–2024)
The table below shows the annual total assets of Recursion Pharmaceuticals Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.45 Billion | +121.60% |
| 2023-12-31 | $653.70 Million | -6.79% |
| 2022-12-31 | $701.29 Million | +14.90% |
| 2021-12-31 | $610.35 Million | +104.41% |
| 2020-12-31 | $298.58 Million | +194.37% |
| 2019-12-31 | $101.43 Million | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation… Read more